A comparison of pregnancy prevention programmes in Europe
Authors:
- Inge ZomerdijkIZInge Zomerdijk
- Miriam SturkenboomMSMiriam Sturkenboom
- Lolkje de Jong-Van Den BergLBLolkje de Jong-Van Den Berg
- Sabine StrausSSSabine Straus
- 8 February 2014
- journal article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 13 (4) , 411-420
Abstract
Pregnancy prevention programmes (PPP) can be imposed by regulatory authorities to minimise the risk of exposure to teratogenic drugs during pregnancy, thus preventing congenital anomalies. The objective of this study was to explore the reasons to request PPPs in the EU and the elements that they included.Keywords
This publication has 17 references indexed in Scilit:
- Evaluation of the effectiveness of risk minimization measuresPharmacoepidemiology and Drug Safety, 2012
- Implementation of the Harmonized EU Isotretinoin Pregnancy Prevention ProgrammeDrug Safety, 2012
- Pregnancy in women with pulmonary hypertensionNetherlands Heart Journal, 2011
- Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of DiseaseToxicological Sciences, 2011
- Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR ProjectPharmacoepidemiology and Drug Safety, 2010
- Isotretinoin Use and Compliance with the Dutch Pregnancy Prevention ProgrammeDrug Safety, 2010
- Medications in Pregnancy and LactationObstetrics & Gynecology, 2009
- Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicityExpert Opinion on Drug Metabolism & Toxicology, 2008
- What Is the Best Approach to Reducing Birth Defects Associated with Isotretinoin?PLOS Medicine, 2006
- THALIDOMIDE AND CONGENITAL ABNORMALITIESThe Lancet, 1962